[{"address1": "4-6 Bligh Street", "address2": "Suite 12.01, Level 12", "city": "Sydney", "state": "NSW", "zip": "2000", "country": "Australia", "phone": "61 2 9423 0881", "fax": "61 2 9423 0881", "website": "https://www.imugene.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia. Its lead products under development azer-cel, an allogeneic CAR T cell therapy in phase 1 clinical trial targeting relapsed/refractory non-hodgkin lymphoma and b-cell acute lymphoblastic leukemia; CF33 VAXINIA, a combination of genomic sequences from various vaccinia virus strains to generate potent virus in phase 1 clinical trial for mixed advanced solid tumours; and CF33 CD19 chimeric antigen receptor T cells therapies to target solid tumours in phase 1 study. The company also develops CF33 oncolytic virotherapy CHECKvacc in phase 1 clinical trial for triple negative breast cancer; HER-VAXX, a B-cell immunotherapy cancer vaccine completed phase 2 clinical trial to target metastatic and advanced gastric cancer; PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling in phase 2 clinical trial to target non-small cell lung cancer; and NeoPOLEM in phase 2 study for MSI-high colorectal cancer. The company has a research collaboration with NeoImmuneTech to enhance cancer treatments. Imugene Limited is based in Sydney, Australia.", "companyOfficers": [{"maxAge": 1, "name": "Mr. Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICD", "age": 68, "title": "Executive Chairman", "yearBorn": 1956, "fiscalYear": 2024, "totalPay": 204303, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Leslie  Chong", "title": "CEO, MD & Executive Director", "fiscalYear": 2024, "totalPay": 878716, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Ursula  McCurry", "title": "Chief Clinical Operations Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. John  Byon M.D.", "title": "Senior Vice President of Clinical Development", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 9, "boardRisk": 9, "compensationRisk": 10, "shareHolderRightsRisk": 1, "overallRisk": 10, "governanceEpochDate": 1740787200, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 0.0, "open": 0.025, "dayLow": 0.024, "dayHigh": 0.025, "regularMarketPreviousClose": 0.0, "regularMarketOpen": 0.025, "regularMarketDayLow": 0.024, "regularMarketDayHigh": 0.025, "payoutRatio": 0.0, "beta": 3.308, "volume": 229719, "regularMarketVolume": 229719, "averageVolume": 141906, "averageVolume10days": 170253, "averageDailyVolume10Day": 170253, "bid": 0.01, "ask": 0.0267, "bidSize": 0, "askSize": 0, "marketCap": 187134368, "fiftyTwoWeekLow": 0.0044, "fiftyTwoWeekHigh": 0.105, "priceToSalesTrailing12Months": -101.72558, "fiftyDayAverage": 0.026112, "twoHundredDayAverage": 0.03315295, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": "NaN", "currency": "USD", "tradeable": false, "enterpriseValue": 165767728, "profitMargins": 0.0, "floatShares": 6245450491, "sharesOutstanding": 7576289792, "heldPercentInsiders": 0.14484, "heldPercentInstitutions": 0.06548, "impliedSharesOutstanding": 7710230016, "bookValue": 0.009, "priceToBook": 2.7444446, "lastFiscalYearEnd": 1719705600, "nextFiscalYearEnd": 1751241600, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -129304336, "trailingEps": -0.01, "enterpriseToRevenue": -90.111, "enterpriseToEbitda": -1.419, "52WeekChange": -0.66890085, "SandP52WeekChange": 0.121255875, "quoteType": "EQUITY", "currentPrice": 0.0247, "recommendationKey": "none", "totalCash": 33742436, "totalCashPerShare": 0.005, "ebitda": -116816240, "totalDebt": 15756991, "quickRatio": 1.959, "currentRatio": 3.08, "totalRevenue": -1839600, "debtToEquity": 24.902, "revenuePerShare": -0.0, "returnOnAssets": -0.42921, "returnOnEquity": -1.00195, "grossProfits": -1839600, "freeCashflow": -92260928, "operatingCashflow": -91926672, "revenueGrowth": -0.844, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": -39.59572, "financialCurrency": "AUD", "symbol": "IUGNF", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "longName": "Imugene Limited", "shortName": "Imugene, Ltd.", "corporateActions": [], "exchange": "PNK", "messageBoardId": "finmb_11113368", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "regularMarketTime": 1741377600, "regularMarketChangePercent": 0.0, "regularMarketPrice": 0.0247, "marketState": "CLOSED", "hasPrePostMarketData": false, "firstTradeDateMilliseconds": 1562333400000, "regularMarketChange": 0.0, "regularMarketDayRange": "0.024 - 0.025", "fullExchangeName": "OTC Markets OTCPK", "averageDailyVolume3Month": 141906, "fiftyTwoWeekLowChange": 0.0203, "fiftyTwoWeekLowChangePercent": 4.6136365, "fiftyTwoWeekRange": "0.0044 - 0.105", "fiftyTwoWeekHighChange": -0.080299996, "fiftyTwoWeekHighChangePercent": -0.76476187, "fiftyTwoWeekChangePercent": -66.89008, "earningsTimestamp": 1740740340, "earningsTimestampStart": 1740740340, "earningsTimestampEnd": 1740740340, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": -0.01, "fiftyDayAverageChange": -0.0014119986, "fiftyDayAverageChangePercent": -0.054074705, "twoHundredDayAverageChange": -0.008452948, "twoHundredDayAverageChangePercent": -0.25496823, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "cryptoTradeable": false, "displayName": "Imugene", "trailingPegRatio": null, "__fetch_time": "2025-03-08"}]